"Polycythemia Vera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Descriptor ID |
D011087
|
| MeSH Number(s) |
C04.588.448.200.500 C15.378.190.250.500 C15.378.190.636.753 C15.378.400.200.500
|
| Concept/Terms |
Polycythemia Vera- Polycythemia Vera
- Primary Polycythemia
- Polycythemia, Primary
- Polycythemias, Primary
- Primary Polycythemias
- Polycythemia Rubra Vera
- Polycythemia Rubra Veras
- Vera, Polycythemia Rubra
- Veras, Polycythemia Rubra
- Polycythemia Ruba Vera
- Polycythemia Ruba Veras
- Ruba Vera, Polycythemia
- Ruba Veras, Polycythemia
- Vera, Polycythemia Ruba
- Veras, Polycythemia Ruba
- Osler-Vaquez Disease
- Disease, Osler-Vaquez
- Osler Vaquez Disease
- Erythremia
- Erythremias
|
Below are MeSH descriptors whose meaning is more general than "Polycythemia Vera".
Below are MeSH descriptors whose meaning is more specific than "Polycythemia Vera".
This graph shows the total number of publications written about "Polycythemia Vera" by people in this website by year, and whether "Polycythemia Vera" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Polycythemia Vera" by people in Profiles.
-
Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. Leuk Res. 2022 08; 119:106903.
-
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res. 2021 10; 109:106629.
-
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020 05 07; 135(19):1696-1703.
-
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013 Sep; 54(9):1989-95.
-
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011 Oct; 80(7):753-9.
-
Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007 Sep 01; 196(5):709-11.